Spots Global Cancer Trial Database for anthracycline
Every month we try and update this database with for anthracycline cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT05748834 | Breast Cancer | Tucatinib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer | NCT03269981 | Breast Neoplasm | Whole breast ir... Whole breast an... | 20 Years - 70 Years | Samsung Medical Center | |
| Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification | NCT02177175 | Breast Cancer | Carvedilol placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma | NCT01343277 | Advanced Liposa... | Trabectedin Dacarbazine | 15 Years - | Janssen Research & Development, LLC | |
| Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen | NCT00191269 | Metastatic Brea... | gemcitabine gemcitabine | 20 Years - 74 Years | Eli Lilly and Company | |
| Effect of Remote Ischaemic Conditioning in Oncology Patients | NCT02471885 | Cardiotoxicity | Remote Ischaemi... Placebo | 16 Years - 80 Years | University College, London | |
| Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | NCT04106492 | Cancer | SQ3370 | 18 Years - | Shasqi, Inc. | |
| Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer | NCT01413828 | Breast Cancer | concurrent sequential | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer | NCT00912444 | Breast Cancer | Docetaxel, Anth... Docetaxel, cycl... | 18 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
| Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification | NCT02177175 | Breast Cancer | Carvedilol placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer | NCT00912444 | Breast Cancer | Docetaxel, Anth... Docetaxel, cycl... | 18 Years - 70 Years | Shanghai Jiao Tong University School of Medicine | |
| Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs | NCT04630275 | Hypogonadism | 18 Years - 65 Years | Herlev Hospital | ||
| Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification | NCT02177175 | Breast Cancer | Carvedilol placebo | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer | NCT01413828 | Breast Cancer | concurrent sequential | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML | NCT05020665 | Nucleophosmin 1... | Entospletinib Placebo Cytarabine Anthracycline | 18 Years - 74 Years | Kronos Bio | |
| Cardiovascular Function in Adult Survivors of Childhood Malignancies | NCT01415999 | Childhood Cance... | 18 Years - 35 Years | The University of Hong Kong | ||
| Cardiovascular Function in Adult Survivors of Childhood Malignancies | NCT01415999 | Childhood Cance... | 18 Years - 35 Years | The University of Hong Kong | ||
| Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | NCT03149120 | Soft Tissue Sar... | Nivolumab Pazopanib | 18 Years - 100 Years | NYU Langone Health | |
| Cardiotoxicity of Cancer Therapy (CCT) | NCT01173341 | Breast Cancer | Echocardiograph... Blood Collectio... Symptoms Questi... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors | NCT04852965 | Anthracycline I... | 18 Years - | Queen's University, Belfast | ||
| Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer. | NCT03983096 | Breast Cancer | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | ||
| Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer | NCT03269981 | Breast Neoplasm | Whole breast ir... Whole breast an... | 20 Years - 70 Years | Samsung Medical Center | |
| EPO906 Therapy in Patients With Advanced Breast Cancer | NCT00035126 | Breast Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| Cardiotoxicity of Cancer Therapy (CCT) | NCT01173341 | Breast Cancer | Echocardiograph... Blood Collectio... Symptoms Questi... | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Remote Ischaemic Preconditioning in Childhood Cancer | NCT03166813 | Cardiotoxicity | Remote Ischaemi... Control | 4 Years - 18 Years | The University of Hong Kong | |
| Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | NCT04106492 | Cancer | SQ3370 | 18 Years - | Shasqi, Inc. | |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | NCT00060944 | Liposarcoma Leiomyosarcoma | Yondelis Yondelis Dexamethasone Dexamethasone | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs | NCT04630275 | Hypogonadism | 18 Years - 65 Years | Herlev Hospital | ||
| Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality-Obs | NCT04630275 | Hypogonadism | 18 Years - 65 Years | Herlev Hospital | ||
| Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | NCT00060671 | Lymphoma, Folli... Lymphoma, Mixed... Lymphoma, Small... Lymphoma, Low-G... | rituximab Pixantrone (BBR... | 18 Years - | CTI BioPharma | |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | NCT05748834 | Breast Cancer | Tucatinib Doxil | 18 Years - | SCRI Development Innovations, LLC | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours | NCT02076620 | Advanced Solid ... Sarcoma, Breast... | L19TNFα Doxorubicin | 18 Years - | Philogen S.p.A. | |
| Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer | NCT04109066 | Breast Cancer | nivolumab paclitaxel (PTX... nivolumab place... anthracycline cyclophosphamid... Endocrine Thera... Surgery | 18 Years - | Bristol-Myers Squibb | |
| EPO906 Therapy in Patients With Advanced Breast Cancer | NCT00035126 | Breast Neoplasm... | epothilone b | 18 Years - 85 Years | Novartis | |
| Remote Ischaemic Preconditioning in Childhood Cancer | NCT03166813 | Cardiotoxicity | Remote Ischaemi... Control | 4 Years - 18 Years | The University of Hong Kong | |
| Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours | NCT01163903 | Advanced Solid ... | pantoprazole so... doxorubicin hyd... | 18 Years - | University Health Network, Toronto | |
| Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen | NCT00191269 | Metastatic Brea... | gemcitabine gemcitabine | 20 Years - 74 Years | Eli Lilly and Company | |
| Markers of Anthracycline-Related Cardiac Muscle Injury | NCT01112800 | Osteosarcoma Ewing's Sarcoma... Rhabdomyosarcom... Non-rhabdomyosa... | - 21 Years | St. Jude Children's Research Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
